Lobaplatin is a diastereometric mixture of
platinum (II) complexes, which contain a 1,2-bis (aminomethyl) cyclobutane stable
ligand and
lactic acid. Previous studies have showed that
lobaplatin plays inhibiting roles in various types of
tumors. However, the role of
lobaplatin in
prostate cancer remains unknown. Cell viability was detected by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium
bromide assay. Cell proliferation was detected by cell colony formation assay. Cell migration and invasion were determined by transwell migration and invasion assay. Cell apoptosis was detected by flow cytometry. The
messenger RNA and
protein expression levels were detected by quantitative real-time polymerase chain reaction and Western blot.
Lobaplatin treatment inhibits cell viability, cell proliferation, cell migration, and invasion, while promotes cell apoptosis of
prostate cancer cell lines DU145 and PC3. Meanwhile,
lobaplatin treatment regulates apoptosis by downregulation of BCL2 expression and upregulation of BAX expression levels. Our study suggests
lobaplatin inhibits
prostate cancer proliferation and migration through regulation of BCL2 and BAX expression.